Dipeptidyl peptidase IV and adenosine deaminase inhibition by Armenian plants and antidiabetic drugs

International Journal of Diabetes and Metabolism

Volumn 19, Issue 2, 2011, Pages 69-74

  Mardanyan, Sona ^a   Sharoyan, Svetlana ^a   Antonyan, Alvard ^a   Zakaryan, Narine ^b  

^a H Buniatian Institute of Biochemistry National Academy of Sciences of Armenia   (Armenia)

^b YEREVAN STATE UNIVERSITY   (Armenia)

Author keywords

Adenosine deaminase; Antidiabetic drugs; Dipeptidyl peptidase IV; Enzyme inhibition; Plant extracts; Type 2 diabetes mellitus

Indexed keywords

ACHILLEA MILLEFOLIUM EXTRACT; ADENOSINE DEAMINASE; ANTIDIABETIC AGENT; ARCTIUM LAPPA EXTRACT; ARTEMISIA ABSINTHIUM EXTRACT; BLACK TEA EXTRACT; CICHORIUM INTYBUS EXTRACT; CINNAMON EXTRACT; DIPEPTIDYL PEPTIDASE IV; GLIBENCLAMIDE PLUS METFORMIN; GLIQUIDONE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36]; GREEN TEA EXTRACT; HELICHRYSUM RUBICUNDUM EXTRACT; HIPPOPHAE RHAMNOIDES EXTRACT; HYPERICUM PERFORATUM EXTRACT; INULA HELENIUM EXTRACT; MELILOTUS EXTRACT; METFORMIN; ONOPORDON ACANTHIUM EXTRACT; ORIGANUM VULGARE EXTRACT; PLANT EXTRACT; PLANTAGO MAJOR EXTRACT; RUBUS CAESIUS EXTRACT; RUMEX CONFERTUS EXTRACT; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIDIABETIC ACTIVITY; ARCTIUM LAPPA; ARTICLE; CHICORY; CLOVE; CONTROLLED STUDY; DRUG MECHANISM; DRUG MIXTURE; ELECAMPANE; ENZYME ACTIVITY; ENZYME INHIBITION; FLOWER; HELICHRYSUM RUBICUNDUM; HYPERGLYCEMIA; MEDICINAL PLANT; ONOPORDON ACANTHIUM; OREGANO; PATHOGENESIS; PLANT LEAF; RUBUS CAESIUS; RUMEX CONFERTUS; SCREENING;

EID: 84856997547     PISSN: 16067754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Drucker DJ. Enhancing Incretin Action for the treatment of Type 2 Diabetics. Diabetes Care 2003; 26: 2929-2940.
2. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic action of glucagon-like peptide-1(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992; 15: 270-276.
3. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
4. Boonacker CJ, Van Noorden CJF. The multifunctional or moonlighting protein. CD26/DPPIV. Eur J Cell Biol 2003; 82: 53-73.
5. Gorell MD, Gysbers V, Mccaughan GW. CD26: Multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001; 54: 249-264.
6. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663-1670.
7. Pauly RP, Rosche F, Wermann M, McIntosh CHS, Pederson RA, Demuth HU. Investigation of GIP(1-42) and GLP-1(7-36) degradation in vitro by dipeptidyl peptidase IV (DPIV) using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS): A novel kinetic approach. J Biol Chem 1996; 271: 23222-23229.
8. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38: 423-428.
9. Mest HJ, Mentlein R Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005; 48: 616-620.
10. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998; 47: 1253-1258.
11. Reimer KM, Holst JJ, Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002; 146: 717-727.
12. Larsen MO, Rolin B, Ribel U, Wilken M, Deacon CF, Svendsen O, Gotfredsen CF, Carr RD.Valine pirrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta cell mass. Exp Diabesity Res 2003; 4: 93-105.
13. Wiedeman PE., Trevillyan JM. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Investig Drugs 2003; 4: 412-420.
14. Hoshino T, Yamada K, Masuoka K, Tsuboi I, Itoh K, Nonaka K, Oizumi K. Elevated adenosine deaminase activity in the serum of patients with diabetes mellitus. Diabetes Res Clin Pract 1994; 25: 97-102.
15. Prakash MS, Chennaiah S, Murthy YSR, Anjaiah E, Rao SA, Suresh C. Altered Adenosine Deaminase Activity in Type 2 Diabetes Mellitus. JIACM 2006; 7: 114-117.
16. Kurtul N, Pence S, Akarsu E, Kocoglu H, Aksoy Y, Aksoy H. Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Medica (Hradec Kralove) 2005; 48: 63-65.
17. Bnouham M, Ziyyat A, Mekhfi H, Tahri A, Legssyer A. Medicinal plants with potential antidiabetic activity - A review of ten years of herbal medicine research. (1990-2000). Int J Diabetes Metab 2006; 14: 1-25.
18. Koch HP, Jager W, Groh U, Plank G. In vitro inhibition of adenosine deaminase by flavonoids and related compounds. New insight into the mechanism of action of plant phenolics. Meth Find Exp Clin Pharmacol 1992; 14: 413-417.
19. Melzig MF. Inhibition of adenosine deaminase activity of aortic endothelial cells by selected flavonoids. Planta Med 1996; 62: 20-21.
20. Lendeckel U, Arndt M, Wolke C, Reinhold D, Kahne T, Ansorge S. Inhibition of human leukocyte function, alanyl aminopeptidase (APN, CD13) and dipeptidylpeptidase IV (DP IV, CD26) enzymatic activities by aqueous extracts of Cistus incanus L. ssp. incanus. J Ethnopharmacol 2002; 79: 221-227.
21. Zhang W, Zhao J, Wang J, Pang X, Zhuang X, Zhu X, Qu W. Hypoglycemic effect of aqueous extract of seabuckthorn (Hippophae rhamnoides L.) seed residues in streptozotocin-induced diabetic rats. Phytotherapy Research 2009; 24: 228-232.
22. Sharoyan S, Antonyan A, Mardanyan S, Lupidi G, Cristalli G. Influence of dipeptidyl peptidase IV on the enzymatic properties of adenosine deaminase. Acta Biochim Pol 2006; 53: 539-546.
23. Mardanyan S, Sharoyan S, Antonyan A, Armenyan A, Cristalli G, Lupidi G. Tryptophan environment in adenosine deaminase: Enzyme modification with N-bromosuccinimide in the presence of adenosine and EHNA analogs. Biochem Biophys Acta 2001; 1546:185-195.
24. Mentlein R, Struckhoff G. Purification of two dipeptidyl aminopeptidase II from rat brain and their action on proline-containing neuropeptides. J Neurochem 1989; 52:1284-1293.
25. Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Communs 2004; 324: 92-97.
26. Green BD, Irwin N, Duffy NA, Gault VA, O'Harte FPM, Flatt PR. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006; 547: 192-199.
27. Hinke SA, Kuhn-Wache K, Hoffmann T, Pederson RA, McIntosh CHS, Demuth H-U. Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1 Biochem Biophys Res Commun 2002; 291: 1302-1308.
28. Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FPM, Flatt PR. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity. Nateglinide is an inhibitor of DPPIV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol 2007; 30;568:278-286.